Shanghai ChemPartner Co, Ltd, (ChemPartner) a wholly-owned subsidiary of ShangPharma Corporation, has expanded its integrated drug discovery research collaboration with Agios, the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism. ChemPartner will provide integrated services in the areas of protein science, HTS, in vitro enzyme assay, cell biology, in vivo pharmacology, etc, for Agio's innovative R&D programme to discover novel clinical candidates for oncology indications.
Michael Hui, founder and CEO of ChemPartner, said, "ChemPartner is pleased to build upon this existing collaboration and work closely with the experienced scientists at Agios to develop new clinical compounds for oncology indications. The partnership demonstrates the strength and breadth of our integrated drug discovery and development capabilities and this is a wonderful opportunity to share expertise and complement strengths."
"Due to the rapid success and progression of our pipeline and platform, Agios has experienced a need for significant resource assistance. ChemPartners has been able to help us address these needs quickly with high quality and quick responsiveness," said Michael Su, vice president of Drug Discovery, Agios Pharmaceuticals. "ChemPartners' flexibility, scientific expertise, problem-solving skills as well as its comprehensive and integrated service platform have made them an invaluable partner in our continuing leadership strategy of the exciting, breakthrough field of cancer metabolism."
Founded in 2003, Shanghai ChemPartner Company Ltd (ChemPartner) is one of the leading contract research organizations providing medicinal chemistry, discovery biology, pharmacology, DMPK, toxicology, process R&D, analytical development, formulation and contract manufacturing services to over 80 pharmaceutical and biotech companies in the world.